CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback